New glucose-based molecules to target damaged brain cells
Novel Glucose dendrimers for targeting injured neurons
This study is exploring a new way to use special sugar-based molecules to help deliver medicine directly to injured brain cells, aiming to improve recovery for people who have had strokes or other brain injuries.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10972937 on NIH RePORTER |
What this research studies
This research focuses on developing innovative dendrimers made from glucose to specifically deliver therapeutic drugs to injured neurons in the brain. By leveraging the increased glucose uptake seen in damaged neurons, the study aims to create a targeted approach that enhances drug delivery without the need for additional targeting agents. The goal is to improve neuroprotection and repair in patients suffering from acute brain injuries, such as those caused by strokes or trauma. The research builds on previous successes in targeting brain inflammation and aims to validate this new method in clinical settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced acute brain injuries, such as strokes or traumatic brain injuries.
Not a fit: Patients with chronic neurological conditions or those who do not have acute brain injuries may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with acute brain injuries, improving recovery and outcomes.
How similar studies have performed: Previous research has shown success in using dendrimers for targeting brain inflammation, indicating potential for this novel approach.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Rangaramanujam, Kannan — Johns Hopkins University
- Study coordinator: Rangaramanujam, Kannan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.